专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5948773A Formulation comprising antibacterial substance and antiulcer substance 失效
标题翻译：制剂含抗菌物质和抗溃疡物质
公开(公告)号：US5948773A
公开(公告)日：1999-09-07
申请号：US863293
申请日：1997-05-27
申请人： Yohko Akiyama , Masafumi Nakao , Naoki Nagahara , Susumu Iwasa
发明人： Yohko Akiyama , Masafumi Nakao , Naoki Nagahara , Susumu Iwasa
IPC分类号： A61K9/16 , A61K9/32 , A61K9/50 , A61K9/58 , A61K31/43 , A61K31/44 , A61K45/06
CPC分类号： A61K45/06 , A61K31/43 , A61K31/44 , A61K9/1617 , A61K9/1635 , A61K9/5078 , A61K9/5084
摘要： The present invention includes a formulation which comprises an antibacterial substance and an antiulcer substance, wherein at least either of them is formulated into a gastrointestinal mucosa-adherent solid preparation. The formulation of the present invention shows long retention time in the gastrointestinal tract because of adhesion to the gastrointestinal tract mucosa, synergetically enhances the pharmaceutical effects of an antibacterial substance, specially antibiotic against Helicobacter pylori (HP) and an antiulcer substance, with very low doses of active ingredients, particularly the anti-HP antibiotic with low prevalence of side effects. The present agent is useful as an anti ulcer agent, showing potent anti-HP activity.
摘要翻译：本发明包括一种制剂，其包含抗菌物质和抗溃疡物质，其中至少任一种被配制成胃肠粘膜粘附固体制剂。本发明的制剂由于与胃肠道粘膜的粘附而在胃肠道中保留时间长，协同增强抗菌物质的药物作用，特别是针对幽门螺杆菌（HP）和抗溃疡物质的抗生素，具有非常低的剂量的活性成分，特别是副作用低的抗HP抗生素。本发明的药剂可用作抗溃疡剂，显示出有效的抗HP活性。

2. 发明授权

US06319904B1 Formulation comprising antibacterial substance and antiulcer substance 失效
标题翻译：制剂含抗菌物质和抗溃疡物质
公开(公告)号：US06319904B1
公开(公告)日：2001-11-20
申请号：US09348313
申请日：1999-07-07
申请人： Yohko Akiyama , Masafumi Nakao , Naoki Nagahara , Susumu Iwasa
发明人： Yohko Akiyama , Masafumi Nakao , Naoki Nagahara , Susumu Iwasa
IPC分类号： A61K3170
CPC分类号： A61K45/06 , A61K9/1617 , A61K9/1635 , A61K9/5078 , A61K9/5084 , A61K31/43 , A61K31/44 , A61K2300/00 , A61K31/415
摘要： The present invention includes a formulation which comprises an antibacterial substance and an antiulcer substance, wherein at least either of them is formulated into a gastrointestinal mucosa-adherent solid preparation. The formulation of the present invention shows long retention time in the gastrointestinal tract because of adhesion to the gastrointestinal tract mucosa, synergetically enhances the pharmaceutical effects of an antibacterial substance, specially antibiotic against Helicobacter pylori (HP) and an antiulcer substance, with very low doses of active ingredients, particularly the anti-HP antibiotic with low prevalence of side effects. The present agent is useful as an antiulcer agent, showing potent anti-HP activity.
摘要翻译：本发明包括一种制剂，其包含抗菌物质和抗溃疡物质，其中至少任一种被配制成胃肠粘膜粘附固体制剂。本发明的制剂由于与胃肠道粘膜的粘附而在胃肠道中保留时间长，协同增强抗菌物质的药物作用，特别是针对幽门螺杆菌（HP）和抗溃疡物质的抗生素，具有非常低的剂量的活性成分，特别是副作用低的抗HP抗生素。本发明的药剂可用作抗溃疡剂，显示出有效的抗HP活性。

3. 发明申请

US20110104666A1 INSULIN RESISTANCE MARKER 审中-公开
标题翻译：胰岛素抵抗标记
公开(公告)号：US20110104666A1
公开(公告)日：2011-05-05
申请号：US12610977
申请日：2009-11-02
申请人： Toshiya Matsubara , Osamu NISHIMURA , Susumu Iwasa , Makoto Watanabe
发明人： Toshiya Matsubara , Osamu NISHIMURA , Susumu Iwasa , Makoto Watanabe
IPC分类号： C12Q1/68 , C07K7/08 , C07K14/00 , C12Q1/02 , C07K16/00 , C07H21/04
CPC分类号： C07K14/52 , C07K14/475 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/68 , G01N2500/04 , G01N2500/10 , G01N2800/042
摘要： It is provided an insulin resistance marker, a method of evaluating insulin resistance, a method of screening a substance that improves insulin resistance, and a pharmaceutical composition for improving insulin resistance. An insulin resistance marker including a polypeptide comprising at least any 15 continuous amino acids in the specific amino acid sequence (sequence of a proepithelin protein). An insulin resistance marker including a polynucleotide selected from the group consisting of a polynucleotide comprising at least any 45 continuous bases in the base sequence encoding the above specific amino acid sequence, and a polynucleotide that is complementary to the polynucleotide.
摘要翻译：本发明提供胰岛素抵抗标记，胰岛素抵抗评价方法，筛选改善胰岛素抵抗的物质的方法以及改善胰岛素抵抗的药物组合物。包括在特定氨基酸序列（前列腺素蛋白的序列）中包含至少15个连续氨基酸的多肽的胰岛素抵抗标记。包括选自包含编码上述特定氨基酸序列的碱基序列中至少任何45个连续碱基的多核苷酸的多核苷酸的多核苷酸和与该多核苷酸互补的多核苷酸的胰岛素抵抗标记。

4. 发明授权

US06482864B1 Sustained-release preparation of physiologically active polypeptide and production thereof 失效
标题翻译：生理活性多肽的缓释制剂及其制备
公开(公告)号：US06482864B1
公开(公告)日：2002-11-19
申请号：US09319023
申请日：1999-05-28
申请人： Yutaka Yamagata , Masafumi Misaki , Susumu Iwasa
发明人： Yutaka Yamagata , Masafumi Misaki , Susumu Iwasa
IPC分类号： A61K4732
CPC分类号： A61K9/1647 , A61K38/27 , Y10S514/964
摘要： A method for producing a sustained-release preparation, which comprises dispersing a physiologically active polypeptide into an organic solvent solution of a biodegradable polymer and removing the organic solvent, wherein the polypeptide is a powder obtained by lyophilizing an aqueous solution of the polypeptide which solution has a water-miscible organic solvent and/or a volatile salt; which improves the ease of handling of the physiologically active polypeptide powder in the process for producing the preparation; which makes it possible to industrially produce the sustained-release preparation in large scale; which provides a sustained-release preparation showing high and stable concentration of the active component in blood in long term, low initial release ratio of the physiologically active polypeptide, and high entrapment ratio of the polypeptide into the sustained-release preparation.
摘要翻译：一种缓释制剂的制备方法，其包括将生理活性多肽分散到生物可降解聚合物的有机溶剂溶液中并除去有机溶剂，其中所述多肽是通过将多肽溶液冻干得到的粉末水混溶性有机溶剂和/或挥发性盐; 这提高了在制备该制剂的过程中易于处理生理活性多肽粉末; 这使得可以大规模地工业生产缓释制剂; 其提供持续释放制剂，其显示出高生产活性多肽的长期，低的初始释放比例以及所述多肽进入缓释制剂的高滞留比，从而高效稳定血液中活性成分的浓度。

5. 发明授权

US5910492A Osteogenic promoting pharmaceutical composition 失效
标题翻译：成骨促进药物组成
公开(公告)号：US5910492A
公开(公告)日：1999-06-08
申请号：US719467
申请日：1996-09-25
申请人： Tetsuo Hoshino , Hiroya Muranishi , Shigehisa Taketomi , Susumu Iwasa
发明人： Tetsuo Hoshino , Hiroya Muranishi , Shigehisa Taketomi , Susumu Iwasa
IPC分类号： A61K9/00 , A61K9/16 , A61K9/20 , A61K47/26 , A61K47/36 , A61K31/67 , A61K31/66
CPC分类号： A61K31/683 , A61K9/0019 , A61K9/1647 , A61K47/26 , A61K47/36 , A61K9/2031
摘要： This invention provides a pharmaceutical composition comprising a non-peptide osteogenic promoting substance and a biodegradable polymer, which can be safely used as a prophylactic/therapeutic agent for various bone diseases (e.g., bone fractures).
摘要翻译：本发明提供了包含非肽成骨促进物质和生物可降解聚合物的药物组合物，其可以安全地用作各种骨疾病（例如骨折）的预防/治疗剂。

6. 发明申请

US20120149026A1 INSULIN RESISTANCE MARKER 审中-公开
标题翻译：胰岛素抵抗标记
公开(公告)号：US20120149026A1
公开(公告)日：2012-06-14
申请号：US13370840
申请日：2012-02-10
申请人： Toshiya Matsubara , Osamu Nishimura , Susumu Iwasa , Makoto Watanabe
发明人： Toshiya Matsubara , Osamu Nishimura , Susumu Iwasa , Makoto Watanabe
IPC分类号： C12Q1/68 , G01N33/53 , C07K16/18 , C07H21/04 , C12Q1/37 , G01N33/566
CPC分类号： C07K14/52 , C07K14/475 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/68 , G01N2500/04 , G01N2500/10 , G01N2800/042
摘要： It is provided an insulin resistance marker, a method of evaluating insulin resistance, a method of screening a substance that improves insulin resistance, and a pharmaceutical composition for improving insulin resistance. An insulin resistance marker including a polypeptide comprising at least any 15 continuous amino acids in the specific amino acid sequence (sequence of a proepithelin protein). An insulin resistance marker including a polynucleotide selected from the group consisting of a polynucleotide comprising at least any 45 continuous bases in the base sequence encoding the above specific amino acid sequence, and a polynucleotide that is complementary to the polynucleotide.
摘要翻译：本发明提供胰岛素抵抗标记，胰岛素抵抗评价方法，筛选改善胰岛素抵抗的物质的方法以及改善胰岛素抵抗的药物组合物。包括在特定氨基酸序列（前列腺素蛋白的序列）中包含至少15个连续氨基酸的多肽的胰岛素抵抗标记。包括选自包含编码上述特定氨基酸序列的碱基序列中至少任何45个连续碱基的多核苷酸的多核苷酸的多核苷酸和与该多核苷酸互补的多核苷酸的胰岛素抵抗标记。

7. 发明授权

US06190695B1 Pharmaceutical composition containing osteogenesis-promoting substance 失效
标题翻译：含有成骨促进物质的药物组合物
公开(公告)号：US06190695B1
公开(公告)日：2001-02-20
申请号：US09246851
申请日：1999-02-09
申请人： Tetsuo Hoshino , Kazuhiro Saito , Susumu Iwasa
发明人： Tetsuo Hoshino , Kazuhiro Saito , Susumu Iwasa
IPC分类号： A61K920
CPC分类号： A61K47/10 , A61K31/40 , A61K31/445 , A61K31/66 , A61K31/683
摘要： This invention provides a pharmaceutical composition comprising a non-peptide osteogenesis-promoting substance and a polyethylene glycol or a derivative thereof, which can be advantageously used as a agent for preventing or treating various bone diseases (e.g., osteoporosis) in view of the high oral absorbability and stability of the active ingredient.
摘要翻译：本发明提供一种药物组合物，其包含非肽促成成骨促进物质和聚乙二醇或其衍生物，其可以有利地用作预防或治疗各种骨疾病（例如骨质疏松症）的药剂活性成分的吸收性和稳定性。

8. 发明授权

US6117455A Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent 失效
标题翻译：无定形水溶性药物活性剂的缓释微胶囊
公开(公告)号：US6117455A
公开(公告)日：2000-09-12
申请号：US535386
申请日：1995-09-28
申请人： Shigeyuki Takada , Tomofumi Kurokawa , Susumu Iwasa
发明人： Shigeyuki Takada , Tomofumi Kurokawa , Susumu Iwasa
IPC分类号： A61K9/16 , A61K9/52 , A61K9/50 , A61F2/00 , A61F9/02 , A61F13/00
CPC分类号： A61K9/1647 , A61K9/1611 , A61K9/1617 , A61K9/1623 , Y10S977/775 , Y10S977/788 , Y10S977/801 , Y10S977/906 , Y10S977/915
摘要： A sustained-release microcapsule contains an amorphous water-soluble pharmaceutical agent having a particle size of from 1 nm-10 .mu.m and a polymer. The microcapsule is produced by dispersing, in an aqueous phase, a dispersion of from 0.001-90% (w/w) of an amorphous water-soluble pharmaceutical agent in a solution of a polymer having a wt. avg. molecular weight of 2,000-800,000 in an organic solvent to prepare an s/o/w emulsion and subjecting the emulsion to in-water drying.
摘要翻译：缓释微胶囊含有粒度为1nm-10μm的无定形水溶性药剂和聚合物。该微胶囊是通过在水相中分散0.001-90％（w / w）的无定形水溶性药剂的分散体制成的。平均在有机溶剂中分子量为2,000-800,000，以制备s / o / w乳液，并对乳液进行水中干燥。

9. 发明授权

US6113941A Substained release microcapsule of physiologically active compound which is slightly water soluble at pH 6 to 8 失效
标题翻译：生理活性化合物的大片释放微胶囊在pH6至8下略微溶于水
公开(公告)号：US6113941A
公开(公告)日：2000-09-05
申请号：US569097
申请日：1995-12-22
申请人： Shigeyuki Takada , Yasushi Nakagawa , Susumu Iwasa
发明人： Shigeyuki Takada , Yasushi Nakagawa , Susumu Iwasa
IPC分类号： A61K9/16 , A61K9/50 , A61K9/52 , A61K31/4164 , A61K31/4184 , A61K31/4192 , A61K31/4196
CPC分类号： A61K31/4164 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K9/1647 , A61K9/5031 , Y10S514/963
摘要： A pharmaceutical preparation is provided by a microcapsule containing a physiologically active substance which is water-soluble only at a pH of about 3 or below, and a polymer which is biodegradable upon oral administration. A process for producing the microcapsule is also provided.
摘要翻译： PCT No.PCT / JP95 / 01905 Sec。 371日期：1996年12月22日 102（e）日期1996年12月22日PCT 1995年9月21日PCT PCT。公开号WO96 / 10397 日期1996年04月11日药物制剂由含有仅在约3以下的pH水溶性的生理活性物质的微胶囊和口服给药时可生物降解的聚合物提供。还提供了一种生产微胶囊的方法。

10. 发明授权

US4517290A Method for enzyme immunoassay and peptide-enzyme conjugate and antibody therefor 失效
标题翻译：酶免疫测定方法和肽酶结合物及其抗体
公开(公告)号：US4517290A
公开(公告)日：1985-05-14
申请号：US533619
申请日：1983-09-19
申请人： Susumu Iwasa , Isamu Yoshida , Koichi Kondo
发明人： Susumu Iwasa , Isamu Yoshida , Koichi Kondo
IPC分类号： C07K5/103 , C07K14/59 , C07K16/26 , C12N9/96 , G01N33/531 , G01N33/535 , G01N33/76 , G01N33/54 , A61K39/395 , G01N33/56
CPC分类号： C12N9/96 , C07K14/59 , C07K16/26 , C07K5/1008 , G01N33/531 , G01N33/535 , G01N33/76 , Y10S435/81 , Y10S435/961 , Y10S435/963 , Y10S435/967 , Y10S435/971 , Y10S435/975 , Y10S436/814 , Y10S530/806 , Y10S930/11
摘要： In an enzyme immunoassay, when a specific antibody produced by contacting a peptide essential to the formation of a specific antibody to a peptide antigen, a freeze-dried material of .beta.-D-galactosidase-enzyme conjugate or a peptide-enzyme conjugate prepared by coupling a labeling enzyme with a peptide of the general formula:H-R.sub.1 -Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln-OHwherein R.sub.1 is a peptide fragment consisting of 1 to 14 amino acid residues including Gly in the 14-position of the peptide Ala.sup.1 -Pro.sup.2 -Pro.sup.3 -Pro.sup.4 -Ser.sup.5 -Leu.sup.6 -Pro.sup.7 -Ser.sup.8 -Pro.sup.9 -Ser.sup.10 -Arg.sup.11 -Leu.sup.12 -Pro.sup.13 -Gly.sup.14 is used, a high reproducibility of the result of the enzyme immunoassay is obtained.
摘要翻译：在酶免疫测定中，当通过将形成特异性抗体所必需的肽与肽抗原接触而产生的特异性抗体，β-D-半乳糖苷酶 - 酶偶联物的冷冻干燥物质或通过偶联制备的肽 - 酶偶联剂具有以下通式的肽的标记酶：H-R1-Pro-Ser-Asp-Thr-Pro-Ile-Leu-Pro-Gln-OH，其中R1是由1至14个氨基酸残基组成的肽片段，包括Gly 在肽Ala1-Pro2-Pro3-Pro4-Ser5-Leu6-Pro7-Ser8-Pro9-Ser10-Arg11-Leu12-Pro13-G ly14的14位中，酶免疫测定结果的高再现性为获得。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式